Latest Retail Distribution News

Xenitra Limited's OPAL Real World Asset tokenised sales ecosystem has generated over $500,000 in sales within its first month, onboarding more than 130 distributors and positioning the company as an early mover in blockchain-enabled FMCG sales in China.

Merino & Co. reported Q3 FY26 revenue of A$441,558 with new domestic and China purchase orders supporting its growth strategy, while cash reserves fell to A$654,282 due to investments in production and marketing.

OMG Group posted a 44% increase in Q3 FY26 net sales, hitting a $6 million annual turnover milestone, while launching a dual matcha brand platform and securing national Woolworths distribution for new oat milk protein flavours.

Bio-Gene Technology is progressing critical toxicology studies for Flavocide with a targeted APVMA submission in March 2027, while forging a strategic partnership to launch Qcide insecticides in Japan by late 2026.

Xenitra Limited has acquired Hong Kong Fukang Trading Co., including key pharmaceutical licenses and ecommerce assets, to fully operationalise its OTC medicine business in Hong Kong and China.

OMG Group has reported a robust 53% increase in net sales for the first two months of FY26, driven by strong growth across retail and ecommerce channels. The company plans a strategic refresh of its Blue Dinosaur product range to maintain momentum.

OMG Group has launched two new matcha brands targeting both premium and mass-market consumers, supported by a five-year exclusive supply agreement for ceremonial-grade Japanese matcha. This move positions OMG to capitalise on the booming global matcha market through a vertically integrated strategy.

Pure Foods Tasmania reports a significant operational turnaround in 1H FY26, driven by strategic cost reductions, expanded distribution deals with major retailers, and the acquisition of premium ice cream brand Elato.

OMG Group has secured a national extension with Woolworths to launch three new high-protein oat milk flavours, aiming to capitalise on growing consumer demand and boost FY26 revenue.

HITIQ Limited reported a $2.9 million loss for the half-year ending December 2025, while making significant strides in international market expansion and strategic partnerships. The company’s capital raising efforts aim to support its transition from technology validation to commercial execution.

Aumake Limited has secured a four-year exclusive global distribution agreement with EZZ Life Sciences, targeting $10 million in sales and expanding its footprint in high-margin nutraceuticals.

HITIQ has made significant strides in expanding its concussion management technology, PROTEQT©, into North America and Australian retail, backed by strong research partnerships and a successful capital raise.